Mitomycin C treatment of advanced, hormone-resistant prostatic carcinoma: a phase II study.
From February 1984 to February 1987, 29 patients with advanced, hormone-resistant prostatic carcinoma were treated with mitomycin-C at a dose of 20 mg/m2 every 6 weeks (15 mg/m2 in patients greater than 75 years old and in those who had undergone previous radiotherapy). In the 27 evaluable patients, there were no complete remissions (CR), 2 partial remissions (PR), 14 stabilizations (STAB), and 11 cases of progressive disease (PRO). Ten stabilized patients showed significant pain reduction. Toxicity was minimal. The actuarial median survival was 10.8 months. In this study, mitomycin C was not active in terms of CR + PR; however, a beneficial symptomatic effect was frequently observed.
Veronesi
A
A
Division of Medical Oncology, Centro di Riferimento Oncologico, Aviano (PN), Italy.
Dal Bo
V
V
Lo Re
G
G
Della Valentina
M
M
Tirelli
U
U
Merlo
A
A
Talamini
R
R
Francini
M
M
Monfardini
S
S
D000368:Aged; D000369:Aged, 80 and over; D004341:Drug Evaluation; D006801:Humans; D008297:Male; D008875:Middle Aged; D016685:Mitomycin; D008937:Mitomycins / Q000009:adverse effects / Q000627:therapeutic use*; D011471:Prostatic Neoplasms / Q000188:drug therapy*
D008937:Mitomycins; D016685:Mitomycin